Blood-based epigenome-wide analyses of cognitive abilities.
Genome Biol
; 23(1): 26, 2022 01 17.
Article
em En
| MEDLINE
| ID: mdl-35039062
ABSTRACT
BACKGROUND:
Blood-based markers of cognitive functioning might provide an accessible way to track neurodegeneration years prior to clinical manifestation of cognitive impairment and dementia.RESULTS:
Using blood-based epigenome-wide analyses of general cognitive function, we show that individual differences in DNA methylation (DNAm) explain 35.0% of the variance in general cognitive function (g). A DNAm predictor explains ~4% of the variance, independently of a polygenic score, in two external cohorts. It also associates with circulating levels of neurology- and inflammation-related proteins, global brain imaging metrics, and regional cortical volumes.CONCLUSIONS:
As sample sizes increase, the ability to assess cognitive function from DNAm data may be informative in settings where cognitive testing is unreliable or unavailable.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Epigênese Genética
/
Epigenoma
Tipo de estudo:
Prognostic_studies
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article